Lifecore Biomedical, Inc. LFCR R2KPHARMA
Company Overview
Lifecore Biomedical, Inc., together with its subsidiaries, operates as an integrated contract development and manufacturing organization that serves customers in the United States, Belgium, the Netherlands, and internationally. It provides services in the development, manufacture, aseptic fill, and finish of formulations and highly viscous sterile injectable pharmaceutical drug or medical device products in syringes, vials, and cartridges in various modalities. The company also manufactures and sells pharmaceutical-grade hyaluronic acid in bulk form, as well as for use in formulated and filled syringes and vials for injectable products used in treating various medical conditions and procedures, including ophthalmic and orthopedic applications. In addition, it offers product development services, including analytical method development and validation, formulation development, sterile filtration, process scale-up, pilot studies, stability studies, process validation, and materials production for clinical studies. The company was formerly known as Landec Corporation and changed its name to Lifecore Biomedical, Inc. in November 2022. Lifecore Biomedical, Inc. was founded in 1965 and is headquartered in Chaska, Minnesota.
Recent Developments
- May 2025 Revenue of $128.87M (+0.5% YoY); net profit $-38.72M.
- Trailing 12 Months Year-on-year growth — revenue +0.5%, earnings -422.3%.
- 5-Year Trend Long-term compounding — revenue CAGR -4.0%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | -4.01% |
| 1 Year: | 0.47% |
Compounded Profit Growth
| 5 Years: | - |
| 1 Year: | -422.29% |
Stock Price Performance
| 1 Year: | -43.15% |
| 6 Months: | -36.78% |
| 3 Months: | -21.85% |
| 1 Month: | -9.09% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)44.52 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
No notable strengths flagged.
CONS
- Revenue declined at -4.0% CAGR over 5 years.
- Trading 50.1% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | LFCR Lifecore Biomedical, Inc. R2KPHARMA | 4.40 | -3.46 | $166.55M | 0.00% | -8.24% | - | -4.01% | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,149.36 | 38.57 | $1.02T | 0.58% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 275.23 | 31.97 | $663.28B | 2.09% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 256.46 | 72.45 | $453.19B | 2.84% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 150.33 | 120.26 | $371.29B | 2.65% | - | 34.70% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 397.14 | 25.54 | $356.47B | 2.33% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 159.99 | 24.20 | $304.10B | 3.03% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 162.70 | 24.36 | $252.33B | 1.98% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | AMGN Amgen Inc. NDXSPXR3KPHARMA | 437.23 | 27.14 | $235.98B | 2.49% | 13.95% | 91.47% | 5.51% | 5.55% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Feb 2016 | May 2016 | Aug 2016 | Nov 2016 | Feb 2017 | May 2017 | Aug 2017 | Nov 2017 | Feb 2018 | May 2018 | Aug 2018 | Nov 2018 | Feb 2019 | May 2019 | Aug 2019 | Nov 2019 | Feb 2020 | May 2020 | Aug 2020 | Nov 2020 | Feb 2021 | May 2021 | Aug 2021 | Nov 2021 | Feb 2022 | May 2022 | Aug 2022 | Nov 2022 | Feb 2023 | May 2023 | Aug 2023 | Nov 2023 | Feb 2024 | Aug 2024 | Nov 2024 | Feb 2025 | May 2025 | Sep 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | 109.06M | 110.16M | 129.29M | 121.27M | 115.78M | 122.46M | 144.91M | 141.08M | 124.67M | 124.56M | 155.55M | 152.78M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | 12.93M | 22.78M | 20.12M | 17.10M | 22.87M | 19.12M | 18.80M | 14.92M | 19.81M | 24.81M | 16.34M | 16.89M | 21.57M | 26.21M | 15.34M | 15.51M | 20.05M | 24.09M | 5.29M | 10.77M | 10.93M | 14.58M | 5.54M | 11.46M | 11.64M | 10.42M | 5.98M | 5.68M | 8.55M | 7.78M | 2.73M | 9.96M | 11.89M | 5.39M | 11.08M | 9.85M | 13.98M | 7.79M | 4.46M | 12.07M |
| Operating Income | -33.62M | - | 5.47M | 3.26M | 4.33M | - | 2.73M | -695.00K | 3.48M | - | -257.00K | 10.00K | 3.24M | - | -4.38M | -6.04M | -15.01M | - | -10.60M | 1.37M | 73.00K | - | -4.22M | 3.69M | -9.64M | - | -3.27M | -5.35M | -6.53M | - | -8.61M | -1.48M | -895.00K | -11.58M | -1.96M | -9.03M | 5.33M | -3.07M | -4.67M | 2.57M |
| Net Income | -21.19M | 4.73M | 3.31M | 1.33M | 3.50M | 2.45M | 2.15M | 487.00K | 16.09M | 6.11M | 190.00K | -584.00K | 1.07M | -262.00K | -4.78M | -6.74M | -11.52M | -15.15M | -12.41M | -11.62M | -6.98M | - | -9.39M | -38.47M | -13.59M | - | -10.97M | -12.81M | -36.51M | - | -10.75M | 14.22M | 15.63M | -16.23M | -6.57M | -14.77M | -1.15M | -9.99M | -14.98M | -6.16M |
| Diluted EPS | -0.78 | 0.17 | 0.12 | 0.05 | 0.13 | 0.09 | 0.08 | 0.02 | 0.57 | - | 0.01 | -0.02 | 0.04 | - | -0.16 | -0.23 | -0.39 | - | -0.42 | -0.40 | -0.24 | - | -0.32 | -1.31 | -0.46 | -1.88 | -0.37 | -0.43 | -1.20 | -1.32 | -0.35 | 0.39 | 0.42 | -0.53 | -0.25 | -0.42 | -0.06 | -0.29 | -0.43 | -0.19 |
| R&D Expense | 1.90M | - | 1.94M | 1.97M | 2.01M | - | 2.72M | 3.37M | 3.11M | - | 2.79M | 2.48M | 2.74M | - | 2.82M | 2.82M | 2.75M | - | 1.74M | 1.59M | 1.64M | - | 1.69M | 1.68M | 2.25M | - | 2.21M | 2.18M | 2.23M | - | 2.15M | 2.10M | 2.17M | 2.19M | 1.92M | 2.04M | 2.10M | 1.96M | 1.22M | 1.54M |
Profit & Loss (Annual)
Figures in USD.
| Metric | May 2010 | May 2011 | May 2012 | May 2013 | May 2014 | May 2015 | May 2016 | May 2017 | May 2018 | May 2019 | May 2020 | May 2021 | May 2022 | May 2023 | May 2024 | May 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 238.22M | 276.73M | 317.55M | 441.71M | 476.81M | 539.26M | 476.92M | 469.78M | 524.23M | 557.56M | 160.07M | 100.87M | 111.27M | 103.27M | 128.26M | 128.87M |
| Gross Profit | 33.77M | 46.70M | 52.14M | 62.76M | 62.56M | 65.41M | 66.78M | 79.21M | 78.34M | 81.00M | 39.39M | 38.94M | 39.07M | 27.98M | 41.85M | 40.30M |
| Operating Income | 7.98M | 8.03M | 14.58M | 24.87M | 20.19M | 18.46M | -20.63M | 14.67M | 13.59M | 5.47M | -25.88M | -8.82M | -11.79M | -21.80M | -8.84M | -17.25M |
| Net Income | 3.98M | 3.92M | 12.70M | 22.59M | 19.14M | 13.54M | -11.64M | 10.59M | 24.83M | 411.00K | -38.19M | -32.29M | -116.72M | -99.56M | 12.01M | -38.72M |
| Diluted EPS | 0.15 | 0.15 | 0.49 | 0.85 | 0.71 | 0.50 | -0.43 | 0.38 | 0.89 | 0.01 | -1.31 | -1.10 | -3.97 | -3.32 | 0.33 | -1.27 |
| R&D Expense | 4.36M | 9.28M | 9.62M | 9.29M | 7.20M | 6.99M | 7.23M | 9.47M | 12.80M | 11.47M | 7.58M | 6.68M | 7.84M | 8.74M | 8.57M | 8.26M |
Balance Sheet (Annual)
Figures in USD.
| Metric | May 2009 | May 2010 | May 2011 | May 2012 | May 2013 | May 2014 | May 2015 | May 2016 | May 2017 | May 2018 | May 2019 | May 2020 | Aug 2020 | Nov 2020 | Feb 2021 | May 2021 | Aug 2021 | Nov 2021 | Feb 2022 | May 2022 | Aug 2022 | Nov 2022 | Feb 2023 | May 2023 | May 2024 | May 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | - | 206.31M | 277.69M | 290.94M | 313.62M | 346.46M | 342.65M | 358.61M | 404.70M | 519.09M | 293.50M | 503.04M | 498.07M | 506.86M | 501.88M | 444.73M | 421.31M | 324.24M | 274.70M | 266.38M | 275.97M | 236.66M | 253.54M | 253.96M | 239.34M |
| Total Equity | - | - | 136.06M | 149.74M | 178.69M | 203.07M | 218.43M | 210.73M | 226.61M | 252.56M | 270.14M | 229.84M | 218.54M | 208.00M | 202.20M | 201.95M | 193.12M | 155.42M | 142.56M | 87.82M | 77.88M | 71.14M | 35.02M | -4.23M | 11.31M | 1.34M |
| Cash & Equivalents | 43.46M | 27.82M | 8.13M | 22.18M | 13.72M | 14.24M | 14.13M | 9.97M | 6.00M | 2.90M | 1.08M | 360.00K | 439.00K | 2.48M | 1.85M | 763.00K | 939.00K | 609.00K | 1.10M | 991.00K | 2.54M | 5.94M | 2.95M | 19.09M | 8.46M | 8.27M |
| Long Term Debt | - | - | 15.50M | 40.30M | 34.37M | 28.32M | 34.17M | 45.97M | 42.30M | 37.36M | 87.19M | 101.36M | 93.92M | 82.00M | 145.05M | 164.90M | 123.83M | 124.19M | 79.60M | 0 | - | - | 98.90M | 84.26M | 100.82M | 130.44M |
| Total Liabilities | - | - | 68.59M | 126.13M | 110.53M | 108.86M | 126.36M | 130.30M | 130.46M | 152.14M | 248.95M | 310.27M | 284.50M | 290.07M | 304.66M | 299.94M | 251.61M | 265.88M | 181.68M | 186.88M | 188.50M | 204.83M | 163.10M | 218.46M | 200.06M | 191.91M |
| Current Liabilities | - | - | 30.70M | 66.68M | 50.75M | 48.39M | 56.16M | 56.34M | 51.45M | 88.38M | 137.09M | 164.39M | 153.69M | 173.88M | 125.31M | 101.85M | 103.65M | 122.39M | 90.40M | 176.58M | 178.74M | 195.62M | 37.40M | 39.29M | 38.87M | 30.18M |
Cash Flows (Annual)
Figures in USD.
| Metric | May 2010 | May 2011 | May 2012 | May 2013 | May 2014 | May 2015 | May 2016 | May 2017 | May 2018 | May 2019 | May 2020 | May 2021 | May 2022 | May 2023 | May 2024 | May 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | 7.48M | 14.47M | 22.18M | 21.23M | - | - | 20.76M | 29.84M | 19.78M | 16.02M | -17.04M | 16.47M | -22.59M | -17.44M | 257.00K | -206.00K |
| Investing Cash Flow | -42.80M | -29.39M | -44.07M | -10.42M | - | - | -40.42M | -25.42M | -35.59M | -96.80M | -23.89M | -12.31M | 79.96M | -4.81M | -18.39M | -6.42M |
| Financing Cash Flow | 19.67M | -4.76M | 35.93M | -19.27M | - | - | 15.42M | -8.80M | 13.29M | 79.03M | 40.02M | -3.42M | -57.02M | 39.70M | 7.51M | 6.42M |
| Capital Expenditure | -5.19M | -6.68M | -5.37M | -8.88M | -14.89M | -17.51M | -39.70M | -23.00M | -33.59M | -44.73M | -12.21M | -19.26M | -26.23M | - | -18.39M | -13.41M |
| Free Cash Flow | 2.29M | 7.79M | 16.81M | 12.35M | - | - | -18.93M | 6.83M | -13.81M | -28.71M | -29.25M | -2.79M | -48.82M | - | -18.14M | -13.62M |
| Share Buybacks | - | 1.18M | 5.01M | - | - | - | - | - | - | - | - | - | - | - | - | - |
Ratios (Annual)
Figures in %.
| Metric | May 2010 | May 2011 | May 2012 | May 2013 | May 2014 | May 2015 | May 2016 | May 2017 | May 2018 | May 2019 | May 2020 | May 2021 | May 2022 | May 2023 | May 2024 | May 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | 14.2% | 16.9% | 16.4% | 14.2% | 13.1% | 12.1% | 14.0% | 16.9% | 14.9% | 14.5% | 24.6% | 38.6% | 35.1% | 27.1% | 32.6% | 31.3% |
| Operating Margin % | 3.4% | 2.9% | 4.6% | 5.6% | 4.2% | 3.4% | -4.3% | 3.1% | 2.6% | 1.0% | -16.2% | -8.7% | -10.6% | -21.1% | -6.9% | -13.4% |
| Net Margin % | 1.7% | 1.4% | 4.0% | 5.1% | 4.0% | 2.5% | -2.4% | 2.3% | 4.7% | 0.1% | -23.9% | -32.0% | -104.9% | -96.4% | 9.4% | -30.0% |
| ROE % | - | 2.9% | 8.5% | 12.6% | 9.4% | 6.2% | -5.5% | 4.7% | 9.8% | 0.2% | -16.6% | -16.0% | -132.9% | 2,353.7% | 106.2% | -2,898.0% |
| ROCE % | - | 4.6% | 6.9% | 10.4% | 7.6% | 6.4% | -7.2% | 4.8% | 4.3% | 1.4% | -20.0% | -2.2% | -12.0% | -10.2% | -4.1% | -8.2% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | WYNNEFIELD CAPITAL INC | 12.42% | 4.70M | $21.35M |
| 2 | Legion Partners Asset Management, LLC | 11.79% | 4.46M | $20.26M |
| 3 | Greenhaven Road Investment Management, L.p. | 8.43% | 3.19M | $14.49M |
| 4 | 325 Capital Llc | 7.65% | 2.90M | $13.15M |
| 5 | Blackrock Inc. | 5.32% | 2.01M | $9.14M |
| 6 | Vanguard Capital Management LLC | 3.40% | 1.29M | $5.85M |
| 7 | Geode Capital Management, LLC | 2.26% | 855.50K | $3.88M |
| 8 | Morgan Stanley | 2.03% | 769.36K | $3.49M |
| 9 | State Street Corporation | 1.76% | 668.03K | $3.03M |
| 10 | Quinn Opportunity Partners, LLC | 1.20% | 453.50K | $2.06M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for LFCR
Lifecore plans customer meetings in Milan this October - Stock Titan
<a href="https://news.google.com/rss/articles/CBMipwFBVV95cUxORzhneTkxVlNVaW5ybXJVa2RDM0NHOGE3ZGVCTG8xMXNRUnpUWE9faEZFM1hUOFpzcUVqS3k0VjhlOW10bzVaRmM5cHlraU9YSk1rZHRSYXVJeG1idmZiUWVYcmZaVU9DLTM4eHZoZEswNFZJX25wZ0xKRnQyR0VwVnU2cmhjUGdLWlZIbV…
Lifecore Biomedical (LFCR) Stock Draws Fresh Price Target Split After FY26 Outlook - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMiowFBVV95cUxQdWtUa0d1TWRCdFpLWDBzY0hTMzRvWXV4aWlKU1Vya0JmbFhWTnRPV003eWZidDJHc1JDSEh2RE5GTjBVblVwbGhfYXlaNGhCX2FhTFlFRlZENmlfRjFobW9TVVZTRW8tc19VdFN4LWQwNElPa2RjTEctbnd2TlZlQk1RNWdDUk1KYTRucF…
A marketed injectable drug is expected to bring Lifecore revenue in 2028. - Stock Titan
<a href="https://news.google.com/rss/articles/CBMiuwFBVV95cUxQeGZLT0VxbWhTT0ZtaVloT3RYNzdqb21BMVdQTWJFbko3YXR0ejdkTDJ3ZThWamVWSDhRUVV4Vk5ObUZFNzNJdnJlSGtXX0ltT1lrNlRSQjJPeHMtUlF4ejlYSE02U1hJZnp6N19zb2pkQUw4cTVqVHZRRFREcThKYXh2aHJFYzF6elZkcW…
LFCR | Lifecore Biomedical, Inc. Common Financials - Revenue Breakdown - quiverquant.com
<a href="https://news.google.com/rss/articles/CBMid0FVX3lxTE9NWkhOckdQdmZ4WEVnZm1kcEpJMDUtMGlCUUVQSGhhN0YxcWNLMjVzZDdsMnhZYlFSWnpSekc5bjBoeGo2akozNzNvVVlMY3BNR0ZHV2hNZS1tcDYwc05XZVV4Y2VUVy0zSmJBRFJ2eGpFUFFwLUk0?oc=5" target="_blank">LFCR | …
Lifecore Biomedical Inc (LFCR) Continues Winning Contracts, Ignored by the Market - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMipgFBVV95cUxOODItU0pHRTBmZklXQTJhUWNvVjBFTEtCTGU4RU1BcURwZWxDWTQ2Q3RNdk5wbl9GTHRfbzRITlVYQ1VTdEpuNE00dXdGdUg5d0IxdzFvRTJXZE1aUkdFUERkaFR5UHRmNklBR3dkN09oOV9oQTJMQVNWS2FSS1Vsd1ZOMmphWWEtaE5XNX…
LFCR - Finviz
<a href="https://news.google.com/rss/articles/CBMiRkFVX3lxTFA0OWxrU1ZoNUtnbzFaYUhVM2k3LVo1dEdZSjlWczNoaTlUNEJuM1pWcTBkU0ZXb3dpcXNCSWktT1Y5ckZnZUE?oc=5" target="_blank">LFCR</a> <font color="#6f6f6f">Finviz</font>…
LFCR — Frequently Asked Questions
What is the current share price of Lifecore Biomedical, Inc. (LFCR)?
As of 2026-09-07 16:24 PDT, Lifecore Biomedical, Inc. (LFCR) trades at $4.40 on NasdaqGS. Its 52-week range is $3.66 to $8.82.
What is the market capitalisation of LFCR?
Lifecore Biomedical, Inc. (LFCR) has a market capitalisation of $166.55M on NasdaqGS.
What is the P/E ratio of LFCR?
LFCR trades at a trailing price-to-earnings (P/E) ratio of -3.46. The industry average P/E is 25.17. Its price-to-book (P/B) ratio is -5.54.
Is LFCR a good stock to buy?
This page provides a data-driven analysis of Lifecore Biomedical, Inc. (LFCR), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.